Cyril Amarchand Mangaldas acted as counsel to EAAA India Alternatives Limited and Avendus Finance Private Limited (“Investors”) on a secured financing aggregating up to INR 5,850,000,000 (Indian Rupees Five Hundred and Eighty Five Crore) raised by Gujarat Themis Biosyn Limited (the “Issuer”). The proceeds of the financing were primarily used by the Issuer to fund part of the consideration for its acquisition of Micro Biopharm Japan Company Limited (“Target Co.”) in Japan.
The transaction team comprised of Abhijeet Das, Partner (Regional Head — Financial Services); and Abhishek Khatri, Partner; with support from Hrishikesh Jaiswal, Jigme Tshering and Shlok Shetty, Associates.
